Promising phase II data reported during last year's American Society of Hematology (ASH) meeting helped Isis Pharmaceuticals Inc. snag big pharma Bayer Healthcare in an alliance for potential first-in-class factor XI inhibitor that brings the Carlsbad, Calif.-based biotech a whopping $100 million up front.